KYOWA KIRIN

📅 Upcoming

🕒 Recent(90d)

News

• Kura spins diabetes work into a Lilly-backed biotech startup
  Caspian Therapeutics aims to develop menin inhibitors, which have proven effective against leukemia, for diabetes and other cardiometabolic conditions.
  biopharma_dive · 17d ago
• Mid-cap biotechs join Trump’s latest round of drug pricing deals
  Focused on Medicaid, the new pacts now involve more than just large pharmaceutical companies, but still aren’t expected to meaningfully impact drugmaker profits.
  biopharma_dive · 25d ago
• STAT+: Pharmalittle: We’re reading about Novartis and Bristol pausing cell therapy trials, a $480K cancer drug, and more
  Novartis and Bristol Myers Squibb have paused multiple cell therapy trials, while $480,000 has now become a routine price for a cancer drug. Read the latest pharma headlines in today's…
  stat · 25d ago
• 9 midsize drugmakers climb aboard Trump’s MFN train
  Astellas Pharma, BridgeBio, BeOne Medicines and six other large biotechs join the 17 Big Pharmas that previously signed on to President Donald Trump’s Most Favored Nation (MFN) drug pricing program…
  biospace · 25d ago
• STAT+: Trump strikes nine more deals with drugmakers to lower prices
  President Trump on Monday announced the next round of pricing deals with drugmakers, with nine new companies making such agreements.
  stat · 25d ago
• Amgen abandoning $500M+ Crohn’s collab won’t derail TScan’s pipeline strategy
  TScan has told Fierce that its pipeline strategy remains unchanged despite Amgen walking away from a Crohn’s disease collaboration that had the potential for a windfall of half a billion dollars.
  fiercebiotech · 1mo ago
• Amgen sheds around 40 staffers amid continuing struggles
  Amgen has laid off around 40 employees as part of “organizational changes” meant to better align operations with the company’s strategic objectives, Fierce has learned.
  fiercebiotech · 2mo ago
• Sanofi halts development of troubled immune drug in eczema
  The decision to no longer seek approval of amlitelimab is the latest setback for a treatment once hailed as a future blockbuster. One analyst expects Sanofi to now pursue “strategic action” to boos…
  biopharma_dive · 2mo ago
• Ipsen’s $450M blood cancer drug; FDA selects first cohort for “pre-check” pilot program
  The planned acquisition of Kartos Therapeutics would hand Ipsen a late-stage asset for myelofibrosis. Elsewhere, Sobi hit a regulatory setback and BeOne unveiled more positive Brukinsa data.
  biopharma_dive · 2mo ago
• FDA Selects Seven Participants for PreCheck Pilot Program to Advance U.S. Drug Manufacturing
  FDA announces the selection of seven companies to participate in the FDA PreCheck Pilot Program, a new initiative designed to boost American global competitiveness, strengthen domestic drug manufac…
  fda_press · 2mo ago